Tauopathies are a group of progressive neurological diseases caused by the accumulation of misfolded tau proteins in the brain. These diseases, which include Alzheimer’s disease and some forms of frontotemporal dementia, are characterized by neuron death and subsequent cognitive and physical decline. Tauopathies are difficult to diagnose and have no known cure; current treatments are mainly palliative. Tau proteins are a class of proteins found in the cytoskeleton of neurons, and are involved in the maintenance of neuronal structure and communication. In healthy cells, tau proteins ensure that the microtubules in a neuron remain stable. In individuals with tauopathies, however, these proteins become misfolded and form accumulations, known as neurofibrillary tangles, around the neuron’s nucleus. As these tau aggregates form, they interfere with the ability of a neuron to transport and process signals. The neurons are effectively ‘clogged up’, and eventually die. As this process continues throughout the brain, it has debilitating effects on cognitive and physical abilities. Due to the complexity of the disease, quality of care is often an issue in tauopathies. Diagnosis can be difficult, since the symptoms of tauopathy diseases can vary from person to person. Furthermore, the development of treatments has been hindered by the difficulty in studying tau accumulation in living brains. There are also ethical concerns in experiments that involve the study of tau pathology in live cells, since the process of accumulation can be slow, making results hard to observe over a viable timescale. Despite these constraints, researchers have made progress in the understanding and treatment of tauopathies, including the development of monoclonal antibodies and other therapies. In conclusion, tauopathies are a group of neurological diseases caused by the misfolding of tau proteins, which disrupt signal transmission and cause neuron death. Current treatments are mainly palliative, and further research is needed to develop effective diagnostic and treatment methods.
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : In silico in vitro and in vivo study of geraniol role in Alzheimer's disease
Bhuvanesh Baniya, Mohanlal Sukhadia University, India
Title : Prince transform: a wave-mechanical framework for real-time EEG analysis and early seizure prediction using chirp and drift detection
Mustafa A Khan, Sevaro Health Inc., United States
Title : Gut-brain axis in autism spectrum disorder: MicroRNAs as a critical mediator of pathogenesis
Rahem Rahmati, Shahrekord University of Medical Sciences, Iran (Islamic Republic of)